Over recent months we have all experienced at first hand the dangers posed by highly infectious diseases. Only a few years ago, this was primarily considered to be a problem in underdeveloped, low-income regions. In 2014, with the aim of saving lives in these regions, Prof. Gérard Krause from the Helmholtz Centre for Infection Research, started to…
After major surgery it’s not unusual for patients in intensive care units to develop complications. If clinical staff could identify at-risk patients early on, it would allow them to react more promptly and save lives. To this end, Prof. Alexander Meyer, physician and computer scientist at the German Heart Center Berlin (DHZB), has developed an…
More than a billion people have no access to medical care, in many cases due to financial obstacles. They have no health insurance, no savings, often not even a bank account. Two physicians at the Charité, Dr. Julius Emmrich and Dr. Samuel Knauß, together with co-founder Elsa Rajemison and her mTOMADY team, have come up with an ingenious solution:…
21 June 2022, Munich and Frankfurt a. M. – A consortium of strong partners has launched the CARMA FUND I as a new vehicle for the translation of promising early-stage life-science projects: the initiators, Ascenion GmbH, a life-science focused technology transfer company of the LifeScience Foundation and the Goethe-University, Frankfurt am…
Supported by Ascenion, the Institute of Molecular Biology (IMBA) and the Vienna BioCenter Core Facilities (VBCF) have signed a licence agreement with TANGO Therapeutics, a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. The agreement provides…
If successful, it would be the first diagnostic method to allow fast, cost-efficient and precise quantification of extracellular nicotinamide adenine dinucleotide (NAD) in human body fluids down to the nanomolar level. NAD is a member of the pyridine nucleotide family, which plays a crucial role in cell-oxidation protection, DNA repair, cell…
16 May 2022, Munich – This year’s hybrid BioVaria brought together over 230 life-science innovators – most of them live in Munich – boosting academia–industry partnering. Following two years of mainly virtual interaction, the event was well received by investors and decision makers from industry as well as academic inventors, entrepreneurs and…
Myxobiotics’ approach is based on a new class of natural compounds (cystobactamids) discovered and developed as antibacterial agents by Prof. Rolf Müller and Prof. Mark Brönstrup and their teams at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Helmholtz Centre for Infection Research (HZI), together with Dr. Thomas…
Leading figures from industry, technology transfer, science and the start-up scene are looking forward to meeting again in person at BioVaria 2022, which will take place in a hybrid format on May 11 and 12, 2022 - live at the Sofitel in Munich and virtually. The portfolio includes around 50 innovative projects from all over Europe - therapeutic…
During her PhD thesis at the Robert-Koch Institute, she delved into the field of patenting and technology transfer when evaluating the societal and commercial potential of her own work in the fields of parasitology, metabolomics and imaging technology. ‘I think the translation of scientific results is an exciting, highly relevant and frequently…
With its innovative approach, Dermagnostix addresses a critical need in dermatology. While therapies have become increasingly effective and specific over recent decades, diagnostic methods have remained largely unchanged. Based on these, many skin diseases are hard to differentiate, and resulting errors lead to wrong therapy…
The MEMUMAB (memory B Cell-based human monoclonal antibodies) approach identifies pathogen-specific antibodies from B cells of recovered or vaccinated individuals and uses these as blueprints for the production of human antibodies for therapeutic application. The process can easily be adapted to various diseases or pathogenic variants.…
On 30 November 2021, Ascenion will host the first GO-Bio Information Webinar as part of our BMBF-funded Life Science Digital Hub project. Participants will have the opportunity to get informed about the Federal Ministry of Education and Research's GO-Bio initial funding programme for early, innovative ideas, listen to talks from successful…
The projects PROTAC and BacDefense were selected for the first SPRIND Challenge (‘A quantum shift for new antiviral agents’) by the Federal Agency for Disruptive Innovation and will each receive up to EUR 700,000 in the first year of the three-year competition.
The PROTAC team led by Prof. Mark Brönstrup at the Helmholtz Centre for Infection…
iThera’s MSOT technology (multispectral optoacoustic tomography) has the unique capability of visualizing optical contrast at high resolution in deep tissue and displaying the image in real time. It is already in use for preclinical and clinical research around the globe and is currently being developed for diagnostic applications. First data…
Every year we look back in amazement at everything our partners in universities, research institutes and hospitals have achieved – partly with our help, and often at an astonishing pace. We are witnessing rapid technological advances and numerous start-ups working at many levels to improve healthcare worldwide, especially in the field of digital…
According to the BMBF, around 10 per cent of people infected with SARS-CoV-2 suffer from long-term symptoms such as fatigue, headache, impaired concentration, breathlessness, and loss of taste and smell.
In order to determine the causes of long COVID and develop therapies, the BMBF are funding 10 selected projects that follow a variety of…
